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ABSTRACT
Background. This study compared the efﬁcacy of regorafenib
and triﬂuridine/tipiracil (TFTD) in patients with metastatic colo-
rectal cancer (mCRC) who are refractory to standard chemo-
therapy, because despite their clinical approval, it still remains
unclear which of these two drugs should be used as initial
treatment.
Materials and Methods. The clinical data of patients with
mCRC who were treated with regorafenib or TFTD and those of
drug-naive patients, between June 2014 and September 2015,
were retrospectively collected from 24 institutions in Japan.
Overall survival (OS) was evaluated using the Cox’s proportional
hazard models based on propensity score adjustment for base-
line characteristics.
Results. A total of 550 patients (223 patients in the regorafenib
group and 327 patients in the TFTD group) met all criteria. The
median OS was 7.9 months (95% conﬁdence interval [CI], 6.8–
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9.2) in the regorafenib group and 7.4 months (95% CI, 6.6–
8.3) in the TFTD group. The propensity score adjusted analy-
sis showed that OS was similar between the two groups
(adjusted hazard ratio [HR], 0.96; 95% CI, 0.78–1.18). In the
subgroup analysis, a signiﬁcant interaction with age was
observed. Regorafenib showed favorable survival in
patients aged <65 years (HR, 1.29; 95% CI, 0.98–1.69),
whereas TFTD was favored in patients aged 65 years (HR,
0.78; 95% CI, 0.59–1.03).
Conclusion.No signiﬁcant difference in OS between regorafenib
and TFTD was observed in patients with mCRC. Although the
choice of the drug by age might affect survival, a clearly predic-
tive biomarker to distinguish the two drugs should be identiﬁed
in further studies.The Oncologist 2018;23:7–15
Implications for Practice: Previous studies of patients with metastatic colorectal cancer refractory to standard chemotherapy had
demonstrated that both regorafenib and triﬂuridine/tipiracil could result in increased overall survival compared with placebo, but
there are no head-to-head trials. This large, multicenter, observational study retrospectively compared the efﬁcacy of regorafenib
and triﬂuridine/tipiracil in 550 patients with metastatic colorectal cancer refractory to standard chemotherapy who had access to
both drugs. Although no difference in overall survival was found between the two drugs in adjusted analysis using propensity score,
regorafenib showed favorable survival in patients aged <65 years, whereas triﬂuridine/tipiracil was favored in patients aged 65
years in the subgroup analysis.
INTRODUCTION
The development of novel drugs for metastatic colorectal can-
cer (mCRC) has progressed, and the median overall survival
(OS) from ﬁrst-line chemotherapy has reached 30 months
[1–3]. Advances in later-line chemotherapy, as well as upfront
chemotherapies with oxaliplatin-containing and irinotecan-
containing regimens in combination with angiogenesis inhibi-
tors or anti-epidermal growth factor receptor (anti-EGFR) anti-
body in patients with wild-type RAS, have signiﬁcantly contributed
to the improvement of the OS duration [4].
Survival beneﬁts of salvage chemotherapy have been dem-
onstrated by both regorafenib and triﬂuridine/tipiracil (TFTD)
treatments. Regorafenib, which is a multimolecular targeted
drug inhibiting angiogenesis and apoptosis [5], has shown to
improve OS compared with placebo in patients with mCRC
refractory to standard chemotherapy in a randomized phase III
trial (CORRECT) [6]. The median OS was 6.4 months in the
regorafenib group and 5.0 months in the placebo group (hazard
ratio [HR] 0.77; 95% conﬁdence interval [CI], 0.64–0.94;
p5 .0052). The improvement of OS after treatment with TFTD,
a thymidine-based nucleic acid analogue and tipiracil hydro-
chloride [7], compared with placebo, has been conﬁrmed in a
global randomized phase III trial (RECOURSE) including patients
with mCRC refractory to standard chemotherapy [8]. The
median OS was 7.1 months in the TFTD group and 5.3 months
in the placebo group (HR 0.68; 95% CI, 0.58–0.81; p< .001).
Based on the results of these pivotal trials, the usage of regora-
fenib and TFTD was approved in Japan in March 2013 and
2014, respectively. Although the eligible patients can receive
both drugs individually, it remains unclear which drug should
be used ﬁrst because of a lack of head-to-head randomized
trials.
The aim of this study was to compare the efﬁcacy between
regorafenib and TFTD in patients with mCRC refractory to
standard chemotherapy, who had access to both drugs, to
determine whether a further prospective comparative trial
should be conducted.
MATERIALS AND METHODS
Patient Population
This study was registered with the University Hospital Medical
Information Network (number UMIN000020416). With
approval from the Ethics Committee of each participating insti-
tution, we retrospectively collected the clinical data of patients
with mCRC who received either regorafenib or TFTD between
June 2014 and November 2015. The requirement for informed
consent was waived because of the retrospective design of this
study. The patients’ follow-up was until September 2016.
Main eligibility criteria were as follows: (a) histologically
conﬁrmed colorectal adenocarcinoma, (b) no prior treatment
with regorafenib and TFTD, (c) previous treatment with ﬂuoro-
pyrimidine, oxaliplatin, irinotecan, bevacizumab, and anti-EGFR
antibody (if the patients had tumor with wild-type KRAS/
NRAS), (d) Eastern Cooperative Oncology Group performance
status (ECOG PS) of 0–2, and (f) adequate organ function. After
clinical data collection and blinded assessment, we excluded
patients who could receive only a speciﬁc drug treatment,
either regorafenib or TFTD, because of comorbidity and/or
medical history.
Endpoints and Statistical Analysis
The primary endpoint was OS, deﬁned as the time from the
start of study treatment to death from any cause. Secondary
endpoints included best response rate and disease control rate
according to the Response Evaluation Criteria in Solid Tumors
version 1.1; progression-free survival (PFS), deﬁned as the time
from the start of study treatment to disease progression or
death from any cause; time to treatment failure (TTF), deﬁned
as the time from the start of study treatment to the termina-
tion from any cause or disease progression; time to ECOG PS
2, deﬁned as the time from the start of study treatment to
decision of an ECOG PS 2; and safety according to the Com-
mon Terminology Criteria for Adverse Events version 4.0.
The primary analysis was performed using the Cox’s propor-
tional hazard model including treatment group and propensity
score for all patients (the observational dataset). A 1:1 match-
ing using the propensity score (propensity score-matched data-
set) was performed as a sensitivity analysis. Patients in the two
groups were matched by a difference of propensity score
within 0.05. Propensity score was calculated with a multivari-
able logistic regression model including 20 prognostic variables
(supplemental online Table 1). The predictive factor for OS was
explored using subgroup analyses and interaction tests. The
clinical outcomes, including OS, PFS, TTF, and time to ECOG PS
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2, were evaluated using the Kaplan-Meier method. Continu-
ous and categorical variables were presented as median (inter-
quartile range: 25%–75%) and number (proportion) of patients,
respectively. Statistical tests were two-sided with 5% signiﬁcant
level. All analyses were performed using the SAS software ver-
sion 9.4 (SAS Institute, Cary, NC, https://www.sas.com/en_us/
home.html).
RESULTS
Patients
The number of patients who met all criteria for inclusion in the
analysis was 550, including 223 patients in the regorafenib
group and 327 patients in the TFTD group (Fig. 1). Thirty-four
patients among excluded patients had comorbidity or medical
history, such as thrombosis, hemorrhage, and cardiac events.
Several characteristics, including primary tumor site, bone
metastasis, number of metastatic organ sites, and initial dose
reduction, were imbalanced between the two groups (Table 1).
Regarding the decision of the therapeutic drug, the physician’s
choice was more frequent in the regorafenib group, whereas
the patient’s request was more frequent in the TFTD group
(p< .001). The rate of initial dose reduction was higher in the
regorafenib group than in the TFTD group (20% vs. 5%;
Figure 1. Patient selection ﬂow diagram.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group
performance status; EGFR, epidermal growth factor receptor;
KRAS, Kirsten rat sarcoma; TFTD, triﬂuridine/tipiracil.
Table 1. Comparison of patients’ characteristics between regorafenib and TFTD groups in the observational dataset
Regorafenib
(n5 223)
TFTD
(n5 327)
Characteristics n (%) n (%) p value
Age, years
Median (IQR) 64 (31–84) 64 (29–86) .77
65 years 107 (48) 156 (48) .95
Sex .43
Male 126 (57) 197 (60)
Female 97 (43) 130 (40)
BMI, kg/m2
18.5 kg/m2 194 (87) 267 (82) .10
ECOG PS .13
0 95 (43) 128 (39)
1 121 (54) 176 (54)
2 7 (3) 23 (7)
Primary tumor site .029
Righta 60c (27) 62c (19)
Leftb 163 (73) 265d (81)
Surgery on primary tumor .83
Yes 176 (79) 255 (78)
Histological grade .60
Well- and moderately-differentiated adenocarcinoma 197 (88) 297 (91)
Other adenocarcinoma 17 (8) 19 (6)
Missing 9 (4) 11 (3)
RAS status .80
Mutant 109 (49) 161 (49)
Missing 6 (3) 6 (2)
Metastatic organ site
Liver 141 (63) 201 (61) .72
Dissemination 37 (17) 73 (22) .10
Bone 8 (4) 45 (14) <.001
(continued)
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Table 1. (continued)
Regorafenib
(n5 223)
TFTD
(n5 327)
Characteristics n (%) n (%) p value
Number of metastatic organ site(s) .004
1 60 (27) 75 (23)
2 106 (48) 124 (38)
3 57 (26) 128 (39)
Intolerable drug
Any drugs 63 (28) 112 (34) .16
Fluoropyrimidine 7 (3) 19 (6) .16
Oxaliplatin 56 (25) 87 (27) .77
Irinotecan 9 (4) 27 (8) .054
Bevacizumab 13 (6) 29 (9) .25
Anti-EGFR antibody 3 (1) 12 (4) .12
Prior regimens .60
3 106 (48) 164 (50)
Duration from initiation of ﬁrst-line chemotherapy .92
18 months 163 (73) 241 (74)
Platelets at baseline .18
400 3 103/mL 7 (3) 20 (6)
Missing 2 (1) 1 (0.3)
Baseline serum albumin .71
3.5 g/dL 95 (43) 149 (46)
Missing 7 (3) 8 (2)
Baseline serum AST .67
40 IU/L 62 (28) 95 (29)
Missing 2 (1) 1 (0.3)
Baseline CRP .89
1.0 mg/dL 100 (45) 141 (43)
Missing 6 (3) 10 (3)
Baseline serum CEA .64
5.0 mg/L 196 (88) 292 (89)
Missing 2 (1) 5 (2)
Decision of therapeutic drug <.001
Patient’s request 27 (12) 104 (32)
Physician’s choice 183 (82) 182 (56)
Comorbidity or others 4 (2) 21 (6)
Unknown 9 (4) 20 (6)
Initial dose reduction
Yes 45 (20) 17 (5) <.001
Reasons for initial dose reduction .54
General health deterioration 11 (24) 6 (35)
Adverse event (prior chemotherapy) 4 (9) 3 (18)
Unknown 14 (31) 4 (24)
Others 16 (36) 4 (24)
aIncluding cecum, ascending colon, and transverse colon.
bIncluding descending colon, sigmoid colon, and rectum.
cOne patient with cecal and sigmoid colonic cancers in the regorafenib group and one patient with cecal and transverse colonic cancers in the
TFTD group.
dTwo patients with descending and sigmoid colonic cancers and one patient with sigmoid colonic and rectal cancers in the TFTD group.
Abbreviations: AST, aspartate aminotransferase; BMI, body mass index; CEA, carcinoembryonic antigen; CRP, C reactive protein; ECOG PS, European
Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IQR, interquartile range; RAS, rat sarcoma; TFTD, triﬂur-
idine/tipiracil.
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p< .001). The median follow-up time was 17.6 months in the
regorafenib group and 17.3 months in the TFTD group.
Efficacy
Events of death were observed in 171 patients (77%) in the
regorafenib group and 247 patients (76%) in the TFTD group.
The median OS was 7.9 months (95% CI, 6.8–9.2) in the regora-
fenib group and 7.4 months (95% CI, 6.6–8.3) in the TFTD group
(Fig. 2A and supplemental online Table 2). There was no signiﬁ-
cant difference between the two groups (unadjusted HR of
TFTD to regorafenib, 1.03; 95% CI, 0.85–1.26; p5 .75). In the
propensity score adjusted analysis for OS, similar results were
observed between the two groups (adjusted HR, 0.96; 95% CI,
0.78–1.18; p5 .69). Moreover, the PFS and time to ECOG PS
2 were similar between the two groups (adjusted HR, 0.94
and 1.00, respectively), although the TTF was longer in the
TFTD group than in the regorafenib group (adjusted HR, 0.81;
95% CI, 0.68–0.97; p5 .025; Fig. 1B–1D and supplemental
online Table 2). Among patients with target lesions (212
patients in the regorafenib group and 307 patients in the TFTD
group), no complete responses were observed and partial
response was found in 3 patients (1%) who received TFTD.
Lastly, the disease control rate was similar between the two
groups (32.1% in the regorafenib group vs. 29.6% in the TFTD
group, p5 .56).
Subgroup Analyses
In the observational dataset, statistical signiﬁcance was
observed only between the interaction of treatment and
patient’s age (p value for interaction5 .012; Fig. 3A). Speciﬁ-
cally, regorafenib showed favorable survival in patients aged
<65 years (HR, 1.29; 95% CI, 0.98–1.69), whereas TFTD was
favored in patients aged 65 years (HR, 0.78; 95% CI, 0.59–
1.03; Fig. 3B). The median OS in the patients aged <65 years
and patients aged 65 years was 10.4 months (95% CI, 8.0–
12.3) and 6.2 months (95%, CI 4.9–7.4) among the regorafenib
group, respectively. The median OS in those patients was 7.0
months (95% CI, 5.8–8.6) and 7.7 months (95% CI, 6.5–8.6)
among the TFTD group, respectively.
Safety and Toxicity
Incidence of grade 3 or more hematologic toxicities was higher
in the TFTD group than in the regorafenib group (39% vs. 13%;
p< .001), particularly the incidence of neutropenia (33% vs.
3%; p< .001; Table 2). In contrast, incidence of grade 3 or
more nonhematologic toxicities was higher in the regorafenib
group than in the TFTD group (47% vs. 13%: p< .001), particu-
larly the incidence of hand-foot skin reaction (20% vs. 0%;
p< .001). Liver dysfunction was observed in 12% of patients in
the regorafenib group, and one of them died because of liver
failure. Treatment-related death was observed in four patients
(2%) of the regorafenib group and two patients (1%) of the
TFTD group.
Discontinuation of Study Treatment and Post-
Treatment
Discontinuation of study treatment because of treatment-
related toxicities was higher in the regorafenib group than in
Figure 2. OS, PFS, TTF, and time to ECOG PS 2 for patients who were treated with regorafenib versus TFTD in the observational dataset.
Kaplan-Meier curves for OS (A), PFS (B), TTF (C), and time to ECOG PS2 (D). Adjusted HRs were calculated using the propensity score.
Abbreviations: CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall
survival; PFS, progression-free survival; TFTD, triﬂuridine/tipiracil; TTF, time to treatment failure.
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the TFTD group (24% vs. 7%; p< .001), whereas the propor-
tion of patients who had ECOG PS2 at discontinuation was
similar between the two groups (p5 .93; Table 3). The cross-
over rate was higher in the regorafenib group than in the
TFTD group (60% vs. 40%; p< .001). The proportion of
patients who were treated with any other chemotherapies
except regorafenib and TFTD was higher in the TFTD group
than in the regorafenib group (12% vs. 5%; p5 .004). In a
post hoc analysis, the median OS in patients who received
the two drugs was 10.5 months (95% CI, 9.2–12.2) in the
regorafenib group and 9.4 months (95% CI, 8.3–10.7) in the
TFTD group (p5 .53).
Sensitivity Analysis
One hundred seventy-four patients in each group were
matched by propensity score. Patients’ characteristics were
well-balanced between the two groups, except the initial dose
reduction (p< .0001; supplemental online Table 3), and no
signiﬁcant difference in OS was observed between the two
groups (adjusted HR, 1.02; 95% CI, 0.81–1.30; p5 .85; supple-
mental online Fig. 1A and supplemental online Table 4).
Progression-free survival, TTF, and time to ECOG PS 2 were
also similar to those in the observational dataset (supplemental
online Fig. 1B–1D and supplemental online Table 3). The HRs
for PFS, TTF, and time to ECOG PS2 were 0.92 (p5 .47), 0.80
(p5 .036), and 1.02 (p5 .85), respectively. In the subgroup
analysis, HRs by age were similar to those in the observational
dataset, although they were not statistically signiﬁcant (p value
for interaction5 .18; supplemental online Fig. 2 and supple-
mental online Table 5). Incidence of grade 3 or more toxicities
and the details of discontinuation of study treatment and post-
treatment were also similar to those in the observational data-
set (supplemental online Tables 6 and 7). In a post hoc analysis,
the median OS in patients who received the two drugs was
10.8 months (95% CI, 9.3–12.6) in the regorafenib group and
9.5 months (95% CI, 9.2–12.1) in the TFTD group (p5 .53).
DISCUSSION
We demonstrated that regorafenib and TFTD have similar efﬁ-
cacy in patients with mCRC refractory to standard chemotherapy
using propensity score analysis. These drugs have been approved
for clinical use in the U.S., Europe, and Japan. However, limited
data comparing the efﬁcacy and safety of regorafenib and TFTD
are available in patients with mCRC refractory to standard chem-
otherapy [9, 10]. We performed a large observational study to
determine the necessity of randomized trials in comparing the
efﬁciency of two regimens; similar OS between regorafenib and
TFTD has been observed in a cross-trial comparison [6, 8].
To reduce the bias for a retrospective study, we used pro-
pensity score analysis. Nevertheless, no signiﬁcant differences
in OS between the two groups were observed, either in the
Figure 3. Subgroup analyses of OS in the observational dataset.
Forest plots with HRs for overall survival (A). Kaplan-Meier curves
for OS according to age<65 years and65 years (B).
Abbreviations: CEA, carcinoembryonic antigen; CI, conﬁdence
interval; ECOG PS, Eastern Cooperative Oncology Group perform-
ance status; HR, hazard ratio; OS, overall survival; RAS, rat sar-
coma; TFTD, triﬂuridine/tipiracil.
Table 2. Comparison of the frequency of treatment-related
grade 3 adverse events in 3% of patients in the obser-
vational dataset
Regorafenib
(n5 223)
TFTD
(n5 327)
Event n (%) n (%) p value
Hematologic toxicities
Any 30 (13) 128 (39) <.001
Neutropenia 6 (3) 107 (33) <.001
Anemia 11 (5) 35 (11) .018
Thrombocytopenia 14 (6) 11 (3) .14
Nonhematologic toxicities
Any 104 (47) 41 (13) <.001
Fatigue 7 (3) 8 (2) .61
Anorexia 10 (4) 18 (6) .69
Febrile neutropenia 0 9 (3) .013
Hypertension 13 (6) 0 <.001
Hand-foot skin reaction 44 (20) 0 <.001
Liver dysfunctionsa 27 (12) 1 (0.3) <.001
Skin disordersb 8 (4) 1 (0.3) .004
aIncluding AST increase, ALT increase, total-bilirubin increase, and
ALP increase.
bIncluding erythema multiforme and Stevens-Johnson syndrome.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase;
AST, aspartate aminotransferase; TFTD, triﬂuridine/tipiracil.
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propensity score-adjustment or propensity score-matching
analyses (HR, 0.96 and 1.02, respectively). The HR for OS was
consistently close to 1.00 in all analyses. Although there were
no signiﬁcant differences in the PFS and tumor response
between the two groups, the TTF was shorter in the regorafe-
nib group than in the TFTD group because the termination
by treatment-related toxicities was more frequent in the regor-
afenib group. In fact, incidence of grade 3 or more nonhemato-
logic toxicities associated with regorafenib was consistent with
the results of the CORRECT trial [6]. We adopted time to ECOG
PS 2 as a surrogate of quality of life assessment because
regorafenib-related toxicities might be associated with decreased
quality of life. However, time to ECOG PS 2 was similar
between the two groups. In addition, similar proportion of
patients with ECOG PS 2 at the study treatment discontinua-
tion was observed between the groups. These results suggest
that regorafenib-related toxicities did not affect progression of
their conditions during treatment and at the discontinuation.
The efﬁcacy outcomes of the two drugs reproduced the
results of previous respective pivotal trials, despite the real-
world setting of this study, because the participants had access
to both drugs [6, 8]. In fact, the proportion of patients who
received subsequent chemotherapies after regorafenib or TFTD
was higher than that in the pivotal trials (65% vs. 26% in the
CORRECT trial and 50% vs. 42% in the RECOURSE trial). How-
ever, one fourth of those patients, who were treated with
TFTD, received any other chemotherapy except regorafenib. The
majority of the subsequent chemotherapies were oxaliplatin-
containing or anti-EGFR antibody-containing regimens (data not
shown), which have been conducted in previous phase II trials;
these regimens were used following a rechallenge strategy [11,
12].The efﬁcacy of regorafenib after failure of TFTD or vice versa
is uncertain and should be determined in a future trial.
In the subgroup analysis for OS, including propensity score-
adjustment and propensity score-matching analysis, regorafenib
was a favorable trend of OS in the younger patients, whereas
TFTD was in the elderly patients. The reasons for this difference
are unclear, but similar trends were observed in the subgroup
analysis of the pivotal trials. Although the OS was signiﬁcantly
longer in the regorafenib group patients than in the placebo
group patients among those aged <65 years (HR, 0.72), no sig-
niﬁcant difference was observed in the OS between the two
groups among patients aged 65 years (HR, 0.86) [13]. In con-
trast, the OS was signiﬁcantly longer in the TFTD group than in
the placebo group, both among patients aged <65 years (HR,
0.74) and those aged 65 years (HR, 0.62) [14]. In our study,
the difference in OS seemed to be higher in the regorafenib
group than in the TFTD group. It might be that regorafenib tol-
erance decreased in elderly patients compared with younger
patients, whereas TFTD tolerance was similar between the two
age groups examined. These results are consistent with clinical
impression; however, they should be conﬁrmed in a prospective
trial because the subgroup analysis has a bias.
This study has several limitations. Firstly, as a retrospective
observational study, it is characterized by bias. To reduce it,
patients were enrolled after the two drugs were approved in
Japan, and an adjusted analysis using propensity score was
established for the patients without comorbidity and/or medical
history who had to receive a speciﬁc drug treatment. Secondly,
all patients who were enrolled in our study were Japanese.
However, no ethnic differences between Japanese and Western
patients were observed in either of the pivotal trials [6, 8, 15].
Finally, the patients whose dosage was reduced at the initiation
dose were included. The initial dose reduction of regorafenib
was reported as one of the prognostic factors in a previous pro-
spective observational study [16]. Nevertheless, in this study,
the initial dose reduction was not included as a propensity score
because no variability was observed before the treatment. A
post hoc analysis was established using the propensity score,
Table 3. Comparison of discontinuation of study treatment and post-study treatment outcomes between regorafenib and
TFTD in the observational dataset
Regorafenib
(n5 223)
TFTD
(n5 327)
Outcome measures n (%) n (%) p value
Discontinuation of study treatment 223 (100) 321 (98)
Reason for discontinuation of study treatment <.001
Disease progression 168 (75) 296 (92)
Treatment-related toxicities 54 (24) 21 (7)
Others 1 (0) 4 (1)
Post-study treatment outcomes
ECOG PS at discontinuation .93
01 1 152 (70) 217 (68)
2 68 (30) 104 (32)
Subsequent chemotherapy
Any chemotherapies 144 (65) 160 (50) <.001
Regorafenib 2 (1) 121 (38) NE
TFTD 131 (59) 0 NE
Others 11 (5) 39 (12) .004
Crossover between both drugsa 134 (60) 127 (40) <.001
aCrossover includes patients who were treated with both regorafenib and TFTD in any lines.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NE, not evaluated; TFTD, triﬂuridine/tipiracil.
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including the initial dose reduction; however, the results were
similar to those in the primary analysis (data not shown).
Clinical predictive markers to distinguish the two drugs
were not identiﬁed in our study. Because clinical outcomes did
not differ between unadjusted and adjusted populations in an
analysis adjusted for patients’ characteristics, it is premature to
conduct a superiority randomized trial. Novel genetic or meta-
bolic predictive biomarkers will be needed for a physician to
decide the appropriate drug for initiating treatment patients
with mCRC. Respective predictive biomarkers have been ana-
lyzed in previous reports [17, 18]; however, no clear biomarkers
that could distinguish the two drugs have been found.
CONCLUSION
Regorafenib and TFTD showed a similar effect on the OS of
patients with mCRC refractory to standard chemotherapy in
the real-world setting, on both unadjusted and adjusted analy-
ses. Although the choice of the drug by age might affect sur-
vival, a clearly predictive biomarker to distinguish the two
drugs should be identiﬁed in further studies.
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Implications for Practice:
Introduction of targeted agents in treatment algorithms of patients with metastatic colorectal cancer (mCRC) has signiﬁcantly
improved median overall survival. Emerging therapeutic options are available for patients with mCRC in 2014. This article reviews
and assesses the available phase II and III data in order to elucidate the best combination and sequence modalities of targeted
therapies in patients with mCRC.
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